TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Monday

Key Points

• TScan Therapeutics (NASDAQ:TCRX) is set to announce its Q2 2025 earnings on August 11, with analysts expecting a loss of ($0.28) per share and revenues of $1.31 million.
• In the previous quarter, TScan reported a loss of ($0.26) per share, exceeding analyst expectations, and its stock is currently priced at $1.66 with a market cap of $93.94 million.
• Analysts' ratings vary, with several firms issuing buy ratings and a consensus price target of $7.80, while major shareholder Lynx1 Capital recently increased its stake, owning over 6.7 million shares.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect TScan Therapeutics to post earnings of ($0.28) per share and revenue of $1.31 million for the quarter.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative return on equity of 55.76% and a negative net margin of 2,974.08%. On average, analysts expect TScan Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TScan Therapeutics Stock Down 0.6%

TCRX traded down $0.01 on Friday, reaching $1.64. The company's stock had a trading volume of 146,244 shares, compared to its average volume of 478,801. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $6.38. The business's 50 day moving average is $1.67 and its 200 day moving average is $1.70. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.55 and a quick ratio of 8.55. The stock has a market cap of $92.81 million, a price-to-earnings ratio of -1.50 and a beta of 0.99.

Insider Activity

In other news, major shareholder Lynx1 Capital Management Lp acquired 1,200,000 shares of TScan Therapeutics stock in a transaction on Tuesday, May 20th. The stock was bought at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the completion of the purchase, the insider owned 7,946,141 shares of the company's stock, valued at $9,535,369.20. This represents a 17.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.35% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TScan Therapeutics stock. Goldman Sachs Group Inc. lifted its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 6.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 170,349 shares of the company's stock after acquiring an additional 9,676 shares during the period. Goldman Sachs Group Inc. owned approximately 0.30% of TScan Therapeutics worth $235,000 at the end of the most recent reporting period. 82.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TCRX has been the subject of several research analyst reports. HC Wainwright lowered their price objective on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Wall Street Zen upgraded TScan Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Finally, Wedbush reiterated an "outperform" rating and set a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $7.80.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.